Last updated: October 29, 2026
ABRYSVO is Pfizer’s bivalent RSV prefusion F-protein vaccine, approved in the United States in 2023 for older adults and maternal immunization. Its commercial trajectory depends on seasonal vaccination demand, evolving CDC recommendations, competition from GSK’s Arexvy and Moderna’s mRESVIA, and Pfizer’s ability to expand uptake among adults aged 18 to 59 at increased risk. Pfizer reported $515 million in ABRYSVO revenue in its first partial launch year, but the product entered a more competitive and less predictable RSV vaccine market in 2024.[1]
ABRYSVO Market Dynamics, Financial Trajectory, Patents, and Competitive Outlook
What is ABRYSVO and how does it work?
ABRYSVO is a non-adjuvanted, bivalent RSV vaccine developed by Pfizer. It contains stabilized prefusion F proteins from RSV subgroups A and B. The vaccine is designed to generate antibodies against the viral fusion protein before RSV enters host cells.
The FDA approved ABRYSVO on May 31, 2023, for adults aged 60 years and older. On August 21, 2023, the FDA approved maternal immunization at 32 through 36 weeks’ gestational age to help protect infants from RSV-associated lower respiratory tract disease during the first six months of life.[2]
In June 2024, the FDA expanded ABRYSVO’s indication to adults aged 18 through 59 who are at increased risk of RSV lower respiratory tract disease.[3]
| Product |
Manufacturer |
Technology |
Main U.S. populations |
| ABRYSVO |
Pfizer |
Bivalent prefusion F-protein vaccine |
Adults 60+, maternal immunization, adults 18-59 at increased risk |
| Arexvy |
GSK |
Adjuvanted RSVPreF3 vaccine |
Adults 60+, with expanded use for certain adults 50-59 at increased risk |
| mRESVIA |
Moderna |
mRNA vaccine encoding RSV prefusion F protein |
Adults 60+ |
| Beyfortus |
Sanofi and AstraZeneca |
Long-acting monoclonal antibody |
Infants and certain young children |
ABRYSVO and Arexvy compete directly for older-adult vaccination. Beyfortus is not a vaccine and competes in infant RSV prevention through a different regulatory and reimbursement pathway.
How large is the ABRYSVO market?
The addressable market is large, but realized demand is highly seasonal and sensitive to public-health policy.
The principal U.S. market includes approximately 70 million adults aged 60 years and older, although the annual vaccinated population is materially smaller. The maternal market is narrower but strategically important because it creates a second indication with a different prescriber base, reimbursement pathway, and public-health rationale.
The adult market has several constraints:
- RSV vaccination is generally seasonal rather than continuous.
- Many older adults received vaccination during the initial 2023 launch period.
- CDC recommendations have changed as clinical and postmarketing data developed.
- Providers must coordinate RSV vaccination with influenza, COVID-19, and pneumococcal vaccination.
- Retail-pharmacy execution is critical because most adult RSV vaccination occurs outside hospitals.
- Maternal uptake depends on obstetrician recommendation, gestational timing, payer coverage, and hospital adoption.
The U.S. market also has a narrow administration window for maternal immunization. ABRYSVO is given during weeks 32 through 36 of pregnancy, generally during September through January in most of the continental United States. Infants born outside the typical RSV season or in jurisdictions with different seasonal patterns may instead receive nirsevimab.
What were ABRYSVO’s reported sales and financial trajectory?
Pfizer reported ABRYSVO revenue of approximately $515 million for 2023, its first commercial year.[1] The figure reflected a partial-year launch, initial stocking, and the beginning of the 2023-2024 RSV season.
| Period |
Reported commercial position |
| 2023 |
Approximately $515 million in global ABRYSVO revenue |
| 2024 |
Expansion into adults 18-59 at increased risk; competition intensified with Moderna’s mRESVIA |
| 2025 onward |
Dependent on repeat annual vaccination, recommendation stability, maternal uptake, and market share |
The product’s revenue curve is unlikely to resemble a conventional chronic-care launch. ABRYSVO revenue is expected to be concentrated in the second half of calendar years, with significant variation based on the severity and timing of RSV seasons.
The first launch year benefited from pent-up demand among older adults and broad interest in new RSV prevention products. Future growth requires repeat vaccination, although the optimal revaccination interval for older adults has remained a central commercial and policy issue. A product that is administered once per season has a large annual opportunity, but it also faces annual budget resets and inventory risk.
Pfizer does not report ABRYSVO as a standalone operating segment. The product is included in Pfizer’s broader vaccine and biopharmaceutical revenue disclosures. As a result, public filings do not provide a separately disclosed ABRYSVO operating margin, gross profit, or exact contribution to Pfizer’s earnings.
How does ABRYSVO compare with Arexvy and mRESVIA?
ABRYSVO competes most directly with Arexvy in older adults and with mRESVIA in the broader adult RSV vaccine market.
| Attribute |
ABRYSVO |
Arexvy |
mRESVIA |
| Company |
Pfizer |
GSK |
Moderna |
| FDA approval |
May 2023 |
May 2023 |
May 2024 |
| Platform |
Bivalent prefusion F protein |
Adjuvanted RSVPreF3 |
mRNA |
| Older-adult positioning |
60+ |
60+ |
60+ |
| Maternal indication |
Yes |
No comparable U.S. maternal indication as of June 2024 |
No |
| Adult high-risk expansion |
18-59 at increased risk |
Certain adults 50-59 at increased risk |
Initial approval focused on older adults |
| Launch-year scale |
$515 million in 2023 revenue |
GSK reported approximately £1.24 billion in 2023 Arexvy sales |
New entrant in 2024 |
GSK had a first-mover advantage in 2023 and generated substantially higher sales than Pfizer’s partial-year ABRYSVO launch. ABRYSVO’s maternal indication gave Pfizer a market segment that Arexvy did not match in the United States.
mRESVIA introduced platform competition rather than a simple product-level comparison. Moderna’s mRNA manufacturing system may support rapid production changes, but market adoption depends on provider familiarity, safety perception, cold-chain execution, and comparative effectiveness data.
What is the FDA regulatory status of ABRYSVO?
ABRYSVO is licensed under a biologics license application, or BLA, rather than approved through a conventional small-molecule new drug application.
The key U.S. regulatory milestones are:
| Date |
Event |
| May 31, 2023 |
FDA approval for adults 60 years and older |
| August 21, 2023 |
FDA approval for maternal immunization at 32-36 weeks’ gestation |
| June 2024 |
FDA expansion to adults aged 18-59 at increased risk |
| 2023 |
European Commission authorization for adults 60+ and maternal immunization |
The FDA has also approved a prefilled syringe presentation for ABRYSVO, reducing preparation steps in some clinical and pharmacy settings. Packaging and administration convenience are commercially relevant because vaccination volume is concentrated in retail pharmacies and seasonal clinics.
What patents protect ABRYSVO, and when does biologic exclusivity expire?
ABRYSVO is protected by a combination of biologic regulatory exclusivity, vaccine composition claims, antigen-design claims, formulation claims, manufacturing processes, and delivery presentations. The public FDA biologics framework does not provide an Orange Book-style patent listing for ABRYSVO.
The BPCIA provides a reference biologic with 12 years of data exclusivity from first licensure. Based on the July 19, 2023 first U.S. licensure date reported for ABRYSVO, the core U.S. reference-product exclusivity period would run to July 19, 2035, subject to statutory treatment of the applicable first licensure and any pediatric exclusivity.[4]
Regulatory exclusivity is separate from patent term. Pfizer may hold patents that expire before or after the 12-year biologic exclusivity period. The commercial barrier therefore depends on:
- Claims covering stabilized prefusion F antigens.
- Claims covering RSV A and RSV B antigen combinations.
- Expression and purification methods.
- Stabilization and storage conditions.
- Vaccine presentations, including prefilled syringes.
- Manufacturing controls that are difficult to replicate at commercial scale.
- Clinical and regulatory know-how not fully disclosed in a patent.
A biosimilar or interchangeable biologic competitor cannot rely on an Orange Book Paragraph IV certification for ABRYSVO. The BPCIA uses a separate patent-information exchange and litigation process.
Are there Paragraph IV challenges or biosimilar risks for ABRYSVO?
No conventional Paragraph IV challenge applies because ABRYSVO is a biologic vaccine, not an FDA-approved small-molecule drug listed in the Orange Book.
The principal future entry risk is a follow-on biologic or comparable RSV vaccine. A biosimilar applicant would face several barriers:
- The reference-product exclusivity period.
- Clinical comparability requirements for a structurally complex antigen.
- Manufacturing validation and consistency requirements.
- The need to demonstrate comparable immune responses and safety.
- Potential patent litigation under the BPCIA.
- The difficulty of obtaining interchangeable status for a preventive vaccine.
A competing vaccine based on a different platform, such as an mRNA vaccine, would not necessarily be a biosimilar. It would likely pursue its own BLA and compete through clinical performance, price, supply, and contracting.
What patent litigation and settlement agreements affect ABRYSVO?
As of June 2024, no publicly reported BPCIA patent litigation or Paragraph IV settlement involving ABRYSVO had materially altered its U.S. commercial position.
The lack of a reported settlement does not remove long-term patent risk. RSV vaccines involve overlapping scientific fields, including prefusion F-protein stabilization, antigen presentation, adjuvant systems, nucleic-acid delivery, and manufacturing processes. A later entrant could challenge specific claims or design around them without relying on ABRYSVO’s biologic license.
Pfizer’s main near-term legal exposure is therefore less likely to come from a conventional generic launch and more likely to involve patent disputes over platform technology, manufacturing methods, or competing RSV vaccine technologies.
What manufacturing and intellectual-property barriers support ABRYSVO?
ABRYSVO manufacturing requires controlled production of prefusion F antigens with consistent conformation, purity, potency, and lot-to-lot performance. These controls can create practical barriers even when individual patent claims are narrow.
Key manufacturing barriers include:
- Maintaining the intended prefusion structure during production and storage.
- Producing both RSV subgroup antigens at commercial scale.
- Demonstrating validated potency assays.
- Managing seasonal inventory without excessive expiry.
- Supporting global supply across different regulatory jurisdictions.
- Maintaining cold-chain and distribution reliability.
The product’s commercial value therefore rests on more than the antigen sequence. Process controls, analytical methods, supplier qualification, and regulatory history can limit effective competition.
What geographic markets are important for ABRYSVO?
The United States is the most important initial market because it has a large older-adult population, extensive pharmacy vaccination infrastructure, and a defined maternal immunization recommendation.
The European market is also significant but more fragmented. National reimbursement decisions, seasonal epidemiology, health-technology assessment, and country-specific vaccination programs affect uptake. Pfizer’s global opportunity includes Latin America, Asia-Pacific, and other markets with aging populations, but launch timing and public procurement structures vary widely.
Geographic expansion can improve annual revenue but also raises manufacturing and pharmacovigilance costs. The maternal indication may have different commercial value by country because some governments favor infant monoclonal antibody programs over maternal vaccination.
What generic launch scenarios exist for ABRYSVO?
Three entry scenarios are commercially relevant.
Early follow-on biologic entry
A competitor could seek licensure after the statutory biologic exclusivity period and challenge Pfizer’s patent estate. This scenario would depend on the competitor’s ability to demonstrate biosimilarity and resolve patent disputes.
Platform-based vaccine competition
An mRNA or protein-based RSV vaccine could gain share without being a biosimilar. This is the most immediate competitive pathway because Moderna’s mRESVIA already established a second major technology platform in the U.S. market.
Low-price public procurement
Government tenders or insurer contracting could reduce net prices without a formal generic launch. This risk is higher in markets where RSV vaccination is purchased through centralized public-health programs.
A rapid price collapse is less likely than in a small-molecule market because manufacturing complexity, seasonal supply planning, and biologic regulatory requirements limit the number of credible suppliers.
How strong is the ABRYSVO commercial and patent estate?
ABRYSVO has a strong regulatory position through multiple approved populations and a 12-year reference biologic exclusivity period. Its commercial position is more mixed because the adult RSV market is seasonal, competitive, and sensitive to public-health recommendations.
| Factor |
Assessment |
| Regulatory breadth |
Strong, with older-adult, maternal, and high-risk adult indications |
| Market access |
Strong in U.S. pharmacies and vaccination channels |
| Competitive intensity |
High, with GSK and Moderna |
| Patent visibility |
Lower than for small molecules because there is no Orange Book patent listing |
| Biosimilar risk before 2035 |
Limited by biologic exclusivity |
| Pricing durability |
Moderate; payer and public-health contracting may pressure net price |
| Revenue predictability |
Moderate to low because demand is seasonal |
| Manufacturing barrier |
Meaningful due to antigen conformation and process controls |
| Strategic value to Pfizer |
High as a diversified vaccine asset, but not separately material to Pfizer’s total revenue |
Key Takeaways
- ABRYSVO generated approximately $515 million in Pfizer revenue in 2023, its first partial commercial year.[1]
- The product has three major U.S. demand pools: adults aged 60 and older, pregnant individuals at 32 through 36 weeks’ gestation, and adults aged 18 through 59 at increased risk.
- GSK’s Arexvy was the leading commercial RSV vaccine in 2023, while Moderna’s mRESVIA increased platform competition in 2024.
- ABRYSVO is a biologic vaccine and does not face a conventional Orange Book Paragraph IV challenge.
- The statutory reference-product exclusivity period is expected to extend to 2035 based on the 2023 first U.S. licensure.
- Revenue will remain seasonal and dependent on vaccination recommendations, repeat uptake, maternal adoption, reimbursement, and inventory control.
- Pfizer’s strongest competitive advantages are its broad indication set, maternal label, commercial infrastructure, and manufacturing experience.
- The main long-term threats are platform-based vaccine competition, public-payer price pressure, and follow-on biologic or patent challenges after the exclusivity period.
FAQs about ABRYSVO market and exclusivity
What is the expected peak sales potential of ABRYSVO?
Public company disclosures did not establish a definitive peak-sales figure by June 2024. The addressable population is large, but annual revenue depends on seasonal vaccination rates, repeat dosing, pricing, and competition from Arexvy and mRESVIA.
Is ABRYSVO covered by Medicare?
Older-adult RSV vaccination is generally covered under Medicare Part D rather than Part B, subject to plan and pharmacy administration rules. Maternal coverage depends on commercial insurance, Medicaid, and applicable public-health policies.
Is ABRYSVO a live vaccine?
No. ABRYSVO is a recombinant protein vaccine based on stabilized prefusion F proteins from RSV subgroups A and B.
Can ABRYSVO be used in infants?
ABRYSVO is used during pregnancy to provide passive antibody protection to infants. It is not administered directly to infants as a routine infant vaccine. Nirsevimab is the principal direct infant immunization alternative.
Does Pfizer have an Orange Book listing for ABRYSVO?
No conventional Orange Book patent listing applies because ABRYSVO is licensed as a biologic vaccine under a BLA. Patent disputes would follow biologic and general patent-law pathways rather than a small-molecule Paragraph IV process.
References
-
Pfizer Inc. (2024). 2023 annual report. Pfizer Investor Relations.
-
U.S. Food and Drug Administration. (2023, May 31). FDA approves first RSV vaccine. https://www.fda.gov
-
U.S. Food and Drug Administration. (2024, June). FDA expands approval of Pfizer’s RSV vaccine to adults 18 through 59 at increased risk. https://www.fda.gov
-
U.S. Food and Drug Administration. (2023). Regulatory information for biosimilars and reference product exclusivity. https://www.fda.gov
-
GSK plc. (2024). Annual report 2023. GSK Investor Relations.
-
European Medicines Agency. (2023). Abrysvo: EPAR - product information. https://www.ema.europa.eu
